CLL Microlearning Series – Video #8: Personal Insights and Practice-Based Learning
Personal Insights and Practice-Based Learning
The CLL treatment landscape is rapidly evolving, offering clinicians a growing range of effective therapies that can be tailored to each patient’s needs
In this video, an APP specializing in CLL reflects on how newer options—particularly zanubrutinib—support more individualized care by balancing efficacy, safety, and patient preferences.
Through real practice experience, the video illustrates how switching between BTK inhibitors can help manage side effects while preserving the benefits of this important treatment class.
What You’ll Learn:
- How recent FDA-approved therapies have expanded the CLL treatment “menu”
- Ways clinicians can personalize therapy using disease features, patient goals, and comorbidities
- Why zanubrutinib’s safety profile makes it a strong option for patients starting or switching BTK inhibitors
- A practice-based example of transitioning from acalabrutinib to zanubrutinib to improve tolerability
- How newer therapies enhance access, flexibility, and quality of life in CLL care